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Sir: Numerous recent reports have demonstrated the oc- 
currence of pain and stress and their many effects in crit- 
ically ill neonates. They emphasize the importance of 
analgesia nd sedation in such patients, usually achieved 
with an opiate/benzodiazepine combination [1, 4]. The 
use of diazepam, a long-acting benzodiazepine, during 
the perinatal period is limited by its long elimination 
half-life and by the accumulation of a hypnotic metabo- 
lite, N-desmethyldiazepam, which leads to prolonged se- 
dation. By contrast, in adults midazolam is a short-acting 
benzodiazepine, and its major metabolite, 1-hydroxy- 
midazolam, is less active than the parent drug. This 
therefore seemed a promising sedative drug for preterm 
neonates and an increase in the use of midazolam in 
neonatal intensive care units has been observed, although 
very limited data concerning pharmacokinetics and phar- 
macodynamics of midazolam in the preterm neonate are 
available. Only Jacqz-Aigrain [3] studied pharmacokine- 
tics of midazolam in ten critically ill neonates (gestational 
age: 34-41 weeks). They showed an elimination half-life 
of 6.52 h, indicating that midazolam in preterm neonates 
is not really short-acting. Furthermore in this study there 
was no clinical evidence of any adverse ffect. 
We have observed several adverse ffects in prema- 
ture neonates with a gestational age below 32 weeks. 
Heart rate and arterial blood pressure decreased directly 
following an intravenous bolus injection of 0.2mg/kg 
midazolam, but the most disturbing'observation was the 
appearance of involuntary epileptiform ovements last- 
ing for 15-30 s. 
The pathogenesis of this phenomenon is speculative, 
but perhaps in these preterm infants the decrease in arte- 
rial pressure and heart rate have also an impact on cere- 
bral blood flow or there is a direct effect of midazolam 
on the brain. 
Before the more frequent use of this drug in our neo- 
natal intensive care units is advocated, the pharmaco- 
kinetics and pharmacodynamics (i.e. using 24-h EEG 
monitoring [2]) of midazolam should be studied. 
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